LEXXW (Lexaria Bioscience) Payments of Debt: $0.00 Mil (TTM As of May. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LEXXW Lexaria Bioscience Corp LEXXW
36 GF Score
Price $0.00
! 4 Warning Signs
View Full Analysis

What is Lexaria Bioscience Payments of Debt?

Lexaria Bioscience LEXXW 36 Payments of Debt is $0.00 Mil as of May. 2026. GuruFocus rates LEXXW with a GF Score™ of 36/100. The stock has 4 warning signs investors should review.

Lexaria Bioscience's Payments of Debt for the three months ended in May. 2026 was $0.00 Mil.

Lexaria Bioscience's Payments of Debt for the trailing twelve months (TTM) ended in May. 2026 was $0.00 Mil.

Lexaria Bioscience Payments of Debt Related Terms

Lexaria Bioscience Payments of Debt Historical Data

* Premium members only.

The historical data trend for Lexaria Bioscience's Payments of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lexaria Bioscience Payments of Debt Chart

Lexaria Bioscience Annual Data
Trend Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Aug23 Aug24 Aug25
Payments of Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.07 -0.05 0.00 0.00 0.00

Lexaria Bioscience Quarterly Data
Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26 May26
Payments of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
LEXXW
36GF Score
Lexaria Bioscience Corp LEXXW
Payments of Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lexaria Bioscience Payments of Debt Calculation

Payments of Debt represents all the cash outflow from debt, including both long-term debt and short-term debt.

Payments of Debt for the trailing twelve months (TTM) ended in May. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Payments of Debt →
What does a Payments of Debt of $0.00 Mil mean?
Lexaria Bioscience (LEXXW) has a Payments of Debt of $0.00 Mil as of May. 2026. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on Lexaria Bioscience and its competitors.
Is Lexaria Bioscience's Payments of Debt too high?
Lexaria Bioscience's current Payments of Debt is $0.00 Mil. Overall, Lexaria Bioscience has a GF Score™ of 36/100, reflecting its overall financial health beyond just this single metric.
How does Lexaria Bioscience's Payments of Debt compare to TPST and LPCN?
Lexaria Bioscience's Payments of Debt of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Payments of Debt for a Biotechnology company?
A good Payments of Debt depends on the Biotechnology industry context. However, Payments of Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Payments of Debt mean?
A high Payments of Debt can signal that a stock is expensive relative to its fundamentals. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on Lexaria Bioscience and its competitors. Lexaria Bioscience's current Payments of Debt is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lexaria Bioscience stock overvalued right now?
Lexaria Bioscience (LEXXW) has a current Payments of Debt of $0.00 Mil. The current Payments of Debt is $0.00 Mil. Lexaria Bioscience's overall GF Score™ is 36/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Payments of Debt calculated?
Payments of Debt is calculated from a company's financial statements. For Lexaria Bioscience (LEXXW), the current Payments of Debt is $0.00 Mil as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Lexaria Bioscience Business Description

Other Exchanges LEXX:USA
Address 740 McCurdy Road, No. 100, Kelowna, BC, CAN, V1X 2P7
Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.
36GF Score

Get the complete analysis for LEXXW

Payments of Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price